Is Bone Biologics Stock a Good Investment?
Bone Biologics Investment Advice | BBLGW |
Not Rated
Examine Bone Biologics Stock
Researching Bone Biologics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company recorded a loss per share of 0.14. Bone Biologics Corp had not issued any dividends in recent years. The entity had 1:6 split on the 10th of June 2025.
To determine if Bone Biologics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Bone Biologics' research are outlined below:
| Bone Biologics Corp is not yet fully synchronised with the market data | |
| Bone Biologics Corp generated a negative expected return over the last 90 days | |
| Bone Biologics Corp has high historical volatility and very poor performance | |
| Bone Biologics Corp has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (4.11 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bone Biologics Corp has accumulated about 4.44 K in cash with (4.12 M) of positive cash flow from operations. | |
| Bone Biologics Corp has a frail financial position based on the latest SEC disclosures |
Bone Biologics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.07) | (1.12) | |
| Return On Capital Employed | (1.21) | (1.15) | |
| Return On Assets | (1.07) | (1.12) | |
| Return On Equity | (1.18) | (1.12) |
Determining Bone Biologics' profitability involves analyzing its financial statements and using various financial metrics to determine if Bone Biologics is a good buy. For example, gross profit margin measures Bone Biologics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Bone Biologics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Bone Biologics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Bone Biologics Corp. Check Bone Biologics' Beneish M Score to see the likelihood of Bone Biologics' management manipulating its earnings.
Evaluate Bone Biologics' management efficiency
The company has return on total asset (ROA) of (0.7773) % which means that it has lost $0.7773 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.2948) %, meaning that it generated substantial loss on money invested by shareholders. Bone Biologics' management efficiency ratios could be used to measure how well Bone Biologics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.12 in 2025. Return On Capital Employed is likely to climb to -1.15 in 2025. At this time, Bone Biologics' Other Current Assets are fairly stable compared to the past year. Other Assets is likely to climb to 1,155 in 2025, whereas Total Current Assets are likely to drop slightly above 2.5 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.30 | 2.41 | |
| Net Current Asset Value | -4.2 K | -4.4 K | |
| Tangible Asset Value | -4.2 K | -4.4 K | |
| Tangible Book Value Per Share | 2.30 | 2.41 | |
| Enterprise Value Over EBITDA | 0.46 | 0.48 | |
| Price Book Value Ratio | 0.41 | 0.43 | |
| Enterprise Value Multiple | 0.46 | 0.48 | |
| Price Fair Value | 0.41 | 0.43 | |
| Enterprise Value | -1.9 M | -2 M |
At Bone Biologics Corp, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Beta 1.28 |
Bone Biologics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bone Biologics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bone Biologics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bone Biologics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bone Biologics' Outstanding Corporate Bonds
Bone Biologics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Bone Biologics Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Bone bonds can be classified according to their maturity, which is the date when Bone Biologics Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Understand Bone Biologics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Bone Biologics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1915 | |||
| Market Risk Adjusted Performance | 137.69 | |||
| Mean Deviation | 12.88 | |||
| Semi Deviation | 17.73 | |||
| Downside Deviation | 30.17 | |||
| Coefficient Of Variation | 903.15 | |||
| Standard Deviation | 28.19 | |||
| Variance | 794.79 | |||
| Information Ratio | 0.1087 | |||
| Jensen Alpha | 3.11 | |||
| Total Risk Alpha | 2.32 | |||
| Sortino Ratio | 0.1016 | |||
| Treynor Ratio | 137.68 | |||
| Maximum Drawdown | 237.6 | |||
| Value At Risk | (20.12) | |||
| Potential Upside | 31.15 | |||
| Downside Variance | 910.41 | |||
| Semi Variance | 314.47 | |||
| Expected Short fall | (20.68) | |||
| Skewness | 2.93 | |||
| Kurtosis | 21.39 |
| Risk Adjusted Performance | 0.1915 | |||
| Market Risk Adjusted Performance | 137.69 | |||
| Mean Deviation | 12.88 | |||
| Semi Deviation | 17.73 | |||
| Downside Deviation | 30.17 | |||
| Coefficient Of Variation | 903.15 | |||
| Standard Deviation | 28.19 | |||
| Variance | 794.79 | |||
| Information Ratio | 0.1087 | |||
| Jensen Alpha | 3.11 | |||
| Total Risk Alpha | 2.32 | |||
| Sortino Ratio | 0.1016 | |||
| Treynor Ratio | 137.68 | |||
| Maximum Drawdown | 237.6 | |||
| Value At Risk | (20.12) | |||
| Potential Upside | 31.15 | |||
| Downside Variance | 910.41 | |||
| Semi Variance | 314.47 | |||
| Expected Short fall | (20.68) | |||
| Skewness | 2.93 | |||
| Kurtosis | 21.39 |
Consider Bone Biologics' intraday indicators
Bone Biologics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Bone Biologics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Bone Biologics Corporate Filings
8K | 26th of June 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
S1 | 24th of June 2025 Report filed by companies planning on going public to register their securities with the U.S. Securities and Exchange Commission (SEC) | ViewVerify |
10Q | 12th of May 2025 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 23rd of April 2025 Other Reports | ViewVerify |
Bone Stock media impact
There is far too much social signal, news, headlines, and media speculation about Bone Biologics that are available to investors today. This information is accessible both publicly - through Bone Biologics' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Bone-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Bone Biologics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Bone Biologics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Bone Biologics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Bone Biologics alpha.
Bone Biologics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Bone Biologics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Bone Biologics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Bone Biologics stock to make a market-neutral strategy. Peer analysis of Bone Biologics could also be used in its relative valuation, which is a method of valuing Bone Biologics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Bone Biologics Corporate Executives
Elected by the shareholders, the Bone Biologics' board of directors comprises two types of representatives: Bone Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bone. The board's role is to monitor Bone Biologics' management team and ensure that shareholders' interests are well served. Bone Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bone Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shunichi Kuroda | CoFounder Board | Profile |
Additional Tools for Bone Stock Analysis
When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.